GL Pharm Tech (204840) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, GL Pharm Tech (204840) reported revenue of 35.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202535.3 billion KRW268 million KRW12 million KRW[source]
202426.0 billion KRW-1.8 billion KRW-2.3 billion KRW[source]
202326.0 billion KRW-3.2 billion KRW-3.7 billion KRW[source]
202216.7 billion KRW-3.3 billion KRW-790 million KRW[source]
202112.4 billion KRW-2.7 billion KRW-3.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202530.7 billion KRW8.4 billion KRW22.3 billion KRW[source]
202429.4 billion KRW7.4 billion KRW22.0 billion KRW[source]
202326.7 billion KRW12.1 billion KRW14.7 billion KRW[source]
202230.0 billion KRW8.1 billion KRW21.9 billion KRW[source]
202125.6 billion KRW3.8 billion KRW21.8 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-1.1 billion KRW-4.3 billion KRW4.2 billion KRW[source]
2024-4.6 billion KRW-1.6 billion KRW6.3 billion KRW[source]
2023-2.8 billion KRW-1.1 billion KRW3.8 billion KRW[source]
2022-1.3 billion KRW-5.4 billion KRW6.1 billion KRW[source]
2021-2.3 billion KRW-1.9 billion KRW868 million KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice